Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Chesney

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 23, 2025
Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trialEdward Chesney, Dominic Oliver, Ananya Sarma, et al.
Neuroscience and Biobehavioral Reviews|June 4, 2026
The subjective effects of △9-tetrahydrocannabinol: A systematic review and dose-response meta-regressionIsabella Goodwin, Dominic Oliver, Edward Chesney, et al.
Journal of Psychopharmacology (Oxford, England)|February 24, 2026
Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for PsychopharmacologyJulia Ma Sinclair, Nicola J Kalk, Stephen J Kaar, et al.
Psychiatry and Clinical Neurosciences|April 18, 2023
Influence of cannabis use on incidence of psychosis in people at clinical high riskLucy A Chester, Lucia R Valmaggia, Matthew J Kempton, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|January 15, 2025
Cannabis Use Cessation and the Risk of Psychotic Disorders: A Case-Control Analysis from the First Episode Case-Control EU-GEI WP2 Study: L'arrêt de l'utilisation du cannabis et le risque de troubles psychotiques: Une analyse cas-témoins tirée de l'étude cas-témoins EU-GEI WP2 centrée sur les premiers épisodes psychotiquesBenjamin W Bond, Bea Duric, Edoardo Spinazzola, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 23, 2025
Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trialEdward Chesney, Dominic Oliver, Ananya Sarma, et al.
Neuroscience and Biobehavioral Reviews|June 4, 2026
The subjective effects of △9-tetrahydrocannabinol: A systematic review and dose-response meta-regressionIsabella Goodwin, Dominic Oliver, Edward Chesney, et al.
Journal of Psychopharmacology (Oxford, England)|February 24, 2026
Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for PsychopharmacologyJulia Ma Sinclair, Nicola J Kalk, Stephen J Kaar, et al.
Psychiatry and Clinical Neurosciences|April 18, 2023
Influence of cannabis use on incidence of psychosis in people at clinical high riskLucy A Chester, Lucia R Valmaggia, Matthew J Kempton, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|January 15, 2025
Cannabis Use Cessation and the Risk of Psychotic Disorders: A Case-Control Analysis from the First Episode Case-Control EU-GEI WP2 Study: L'arrêt de l'utilisation du cannabis et le risque de troubles psychotiques: Une analyse cas-témoins tirée de l'étude cas-témoins EU-GEI WP2 centrée sur les premiers épisodes psychotiquesBenjamin W Bond, Bea Duric, Edoardo Spinazzola, et al.
Pageof 5